$237.10
0.540.23%
al cierre: Aug 28, 5:00 PM EST
$240.00
2.901.22%
After hour: Aug 28, 6:14 PM EST
Alnylam Pharmaceuticals Inc
ALNYNASDAQ
Alnylam Pharmaceuticals Earnings & Forecasts
Alnylam Pharmaceuticals (ALNY) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Alnylam Pharmaceuticals Guidance
Alnylam Pharmaceuticals (ALNY) publicó su última previsión de julio 30, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $5.28B - $5.72B para el período.
En comparación con la previsión anterior, Alnylam Pharmaceuticals mantenido redujo su previsión de ingresos desde un rango anterior de $5.3B - $5.8B.
Alnylam Pharmaceuticals ha emitido 16 actualizaciones de orientación entre el octubre 27, 2022 y el julio 30, 2026. During this period, the company raised its outlook 7 times, reflecting management's growing confidence in business performance.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $2.00 | $1.36 | $1.20 | $1.23 |
| Actual | $1.84 | $1.99 | $1.25 | $2.90 |
| Surprise | -8.00% | +46.3% | +4.17% | +135.8% |
| Revenue | ||||
| Estimate | $1.32B | $1.12B | $1.15B | $992.5M |
| Actual | $1.29B | $1.17B | $1.10B | $1.25B |
| Surprise | -2.02% | +4.26% | -4.64% | +25.9% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $2.19 | $2.61 | $2.01 | $2.49 |
| Revenue | ||||
| Consensus | $1.44B | $1.58B | — | — |